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Hepatotoxicity has remained a serious complication limiting the efficacy of highly active 
antiretroviral therapy (HAART) regimen. While this challenge continues to exist, finding possible 
solutions continues to attract scientific solutions.  
Materials and Method:  
Sixty- three adult male Sprague-Dawley rats were used for the study and were divided into 9 groups 
(A-I). Group A received HAART cocktail (Lamivudine, Stavudine & Nevirapine), Group B 
received HAART and H. hemerocallidea extract (100 mg/kgbw), Group C received HAART and H. 
hemerocallidea extract (200 mg/kgbw), Group D received HAART  and vitamin C, Group E 
received HAART and vitamin E, Group F received HAART, vitamin C and vitamin E, Group G 
received H. hemerocallidea extract (100 mg/kgbw), Group H received H. hemerocallidea extract 
(200 mg/kgbw), and Group I received water as placebo. The experiment lasted for 56 days after 
which, the animals were sacrificed, the liver were harvested and prepared for histological 
examination and blood samples were collected through cardiac puncture and centrifuged to get the 
serum for biochemical assessment. 
Results 
While no mortality was reported, animals treated with adjuvant HAART and AP recorded least 
%body weight gain. Significant derangements in serum lipid profiles were exacerbated by treatment 
of with AP as LDL (increased p<0.03), TG (increased p<0.03) with no change in total cholesterol 
levels. Adjuvant AP with HAART recorded reduced LDL (p<0.05 and 0.03), increased HDL 
(p<0.05) and TG (p<0.05 and 0.001). Markers  of liver injury assayed showed significant increase 
(p<0.003, 0.001) in AST in AP alone as well as HAART+ vitamins C and E groups respectively. 
Adjuvant HAART and AP and vitamins C and E also caused significant declines in ALT and ALP 
levels. Serum GGT were not markedly altered. Histopathological derangements ranged from severe 
hepatocellular distortions, necrosis and massive fibrosis following co-treatment of HAART with 
vitamins C and E as well as HAART alone.  
Conclusion 
The results warrant caution on the adjuvant use of H. hemerocallidea with HAART by PLWHAs as 
implications for hepatocellular injuries are suspect with untoward cardio metabolic changes. More 
vigilant monitoring of patients at risk of antiretroviral toxicity is necessary and may prove helpful. 





1.1      Background 
The Centers for Disease Control and Prevention first described human immunodeficiency syndrome 
and acquired immune deficiency syndrome (HIV/AIDS) in 1981 (Fenton and Silverman, 2008). 
Since then, HIV/AIDS have reached epidemic proportions affecting millions of people globally. 
HIV is of retrovirus family that can lead to AIDS, a condition in humans in which the immune 
system begins to fail leading to life threatening opportunistic infections such as tuberculosis, 
pneumonia, diarrhea, meningitis and tumors (Brooks et al., 2010). HIV is spread from human to 
human through direct sexual contact with sexual fluids and blood (Schreibman and Friedland, 
2003).  Infants can also be exposed to the virus through pregnancy and lactation (Schreibman and 
Friedland, 2003).   The virus targets the immune system, in particular the CD4 lymphocytes also 
referred to as T-helper lymphocyte cells which are involved in protecting the body against infection 
(Fenton and Silverman, 2008).   
According to the UNAIDS Report on the global AIDS epidemic (2008) there were an estimated 33 
million people living with HIV in 2007 (UNAIDS, 2010).  Sub-Saharan Africa, the geographical 
region most heavily affected by this epidemic accounts for 67% of all people living with HIV 
(UNAIDS, 2010). Famine, droughts, floods, poverty, food insecurity, war and political insecurities 
are common factors that affect the lives of people living in this region (Spencer et al., 2007).  
Reports have shown that during 2007 72% of AIDS deaths occurred in Sub-Saharan Africa 
(UNAIDS, 2010).   
The introduction of highly active antiretroviral therapy (HAART) has led to a significant reduction 
in AIDS-related morbidity and mortality.  HAART usually consists of a combination of at least 
three antiretroviral agents used with the intent to suppress viral replication and progression of HIV 
disease (Montessori et al., 2004). Due to HAART, HIV has become a manageable chronic 
condition, which results in an increase in life expectancy.  
Despite substantial benefits of HAART, a variety of adverse effects have been associated with their 
use which reduces adherence and efficacy levels of the medication (d‟Arminio et al., 2000). 
Metabolic complications including insulin resistance, glucose intolerance, lactic acidosis, liver 
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enzyme abnormalities, anemia, osteopenia and fat abnormalities (lipodystropy and dyslipidemia) 
have been associated with long-term usage of antiretroviral medications and occur in approximately 
half of all HAART-treated patients, (Carr, 2003; Montessori et al., 2004).  Apart from underlying 
metabolic conditions, patients often have difficulties eating due to side effects like nausea, vomiting 
and loss of appetite and coupled with increased incidence of diarrhea these patients are at a high risk 
of becoming malnourished (Spencer et al., 2007). Among other toxicities associated with HAART, 
hepatotoxicity has also been another complication bedeviling the use of most antiretroviral drugs 
like zidovudine, stavudine or didanosine (Walker et al., 2004). 
Sulkowski et al., (2000) observed that 18 out of 31 drugs causing hepatotoxicity in humans showed 
toxicity in liver enzymes in animals. The liver functions in the digestion of food, the formation of 
excretory products, the degradation of complex cellular materials (e.g., hemoglobin), the 
detoxification  of unnatural compounds, the synthesis of plasma proteins, and the maintenance of 
energy and vitamin stores. Because of this functional complexity, and the dependence of liver 
function on its structure, any changes in liver anatomy become important considerations in the study 
of diseased or abnormal organisms (Champetier et al., 1985). 
The human liver is fairly similar to that of mammals such as the presence of lobes and ligaments in 
its external surface and also functionally heterogeneous with the presence of lobules. The rat liver 
shares some common similarities with the human liver. 
1.1.1      Gross anatomy of the rat liver 
The rat liver is multilobulated as in other mammals. In rats, the liver mass represents approximately 
5% of the total body weight, while in adult humans it represents 2.5% (Kongure et al., 1999). It has 
three surfaces: superior, inferior and posterior. The superior surface comprises a part of the left 
lateral lobes and medial lobes, and as a whole, is convex, and fits under the vault of the diaphragm. 
It is completely covered by the peritoneum, except along the line of attachment of the falciform 
ligament. The inferior surface is concave and is in relation to the stomach, duodenum, right colic 
flexure, the superior part of the pancreas, the right kidney and suprarenal gland (Kongure et al., 
1999).   
Although the rat liver inferior surface does not have the fossae in the shape of the letter H as in 
humans. This surface is almost completely invested by the peritoneum. The posterior surface is not 
covered by the peritoneum over some part of its extent, and is in direct contact with the diaphragm. 
It extends obliquely between the caudate lobe and the bare area of the liver (Kongure et al., 1999).  
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However, similar to the human liver, the rat liver is connected to the under surface of the diaphragm 
and to the anterior wall of the abdomen by five ligaments: the falciform, the coronary, and the two 
laterals are peritoneal folds; the fifth, the round ligament, is a fibrous cord, the obliterated umbilical 
vein. The liver is also attached to the lesser curvature of the stomach by the hepatogastric ligament 
and to the duodenum by the hepatoduodenal ligament (Lorente et al., 1995). 
The rat liver lobes, like the human liver, are named after the portal branches that supply them. The 
medial lobe (ML) is the largest, accounting for approximately 38% of the liver weight. It has a 
trapezoidal shape and is fixed in the diaphragm and abdominal wall by the falciform ligament. It is 
subdivided by a vertical fissure into a large right medial lobe and a smaller left medial lobe 
(Bismuth, 1982). 
The right lobe (RL) is located on the right of the vena cava and posteriorly in the right 
hypochondrium and is almost completely covered by the medial lobe. It comprises about 22% of the 
liver weight and is divided by a horizontal fissure into two pyramidal-shaped lobules called superior 
right lobe and inferior right lobe. The left lateral lobe (LLL) has a rhomboid shape, is flattened and 
situated in the epigastric and left hypochondriac regions over the anterior aspect of the stomach. Its 
medial portion is covered by the left part of the medial lobe. Its upper surface is slightly convex and 
is molded on the diaphragm. It has no fissures. The caudate lobe (CL) is situated behind the LLL 
and on the left of the vena porta and inferior cava vein. It comprises 8-10% of the liver weight. The 






Figure 1.1:   Schematic illustration of the gross anatomy of the rat liver (Adapted from www. 













1.1.2      Histology of the liver 
The basic functional unit of the liver is the liver lobule. A single lobule is about the size of a sesame 
seed and is roughly hexagonal in shape (David et al., 2005).  The primary structures in a lobule 
include: 
a. Plates of hepatocytes form the bulk of the lobule 
b. Portal triads at each corner of hexagon  
c. Central vein  
d. Liver sinusoids that run from the central vein to the portal triads  
e. Hepatic macrophages (Kupffer cells)  
f. Bile canaliculi (“little canals”) – formed between walls of adjacent hepatocytes  
g. Space of Disse – a small space between the sinusoids and the hepatocytes. 
The portal triads consist of three vessels: a hepatic portal arteriole, a hepatic portal venule, and a 
bile duct.  The blood from the arteriole and the venule both flow in the same direction, through the 
sinusoids toward the central vein, which eventually leads to the hepatic vein and the inferior vena 
cava.  Secreted bile flows in the opposite direction, through the bile canaliculi away from the central 
vein, toward the portal triad, and exiting via the bile duct.  As blood flows through the sinusoids and 
the space of Disse toward the central vein, nutrients are processed and stored by the hepatocytes, 
and worn out blood cells and bacteria are engulfed by the Kupffer cells (David et al., 2005).    
The liver has 5 cell types: hepatocytes, Kupffer cells, sinusoidal endothelial cells, bile duct 
epithelial cells and Ito cells.    
Hepatocytes represent 60% of the liver‟s cells, and about 80% of the liver‟s total cell mass.  Most of 
the liver‟s synthetic and metabolic capabilities are functions of the hepatocytes.  Hepatocytes are 
arranged in plates only a single cell thick.  Blood flowing toward the hepatic vein within the space 
of Disse passes both exposed surface areas of the hepatocyte plates, and toxins and nutrients within 
the blood are extracted by the hepatocytes (Saxena et al., 1999). 
Kupffer cells are macrophages that reside in the sinusoids.  These cells help clear out old red blood 
cells and bacteria.  They also break down heme (the iron-containing pigment in hemoglobin) into 
bilirubin, which then becomes one of the chief pigments of bile.  A later by-product of bilirubin 
gives feces its characteristic brown color (Saxena et al., 1999). 
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Sinusoidal endothelial cells are fenestrated meaning they have large pores that allow most proteins 
to pass freely through the sinusoidal endothelium into the space of Disse, where they can make 
direct contact with hepatocytes.  The pores are also bi-directional, meaning that proteins created by 
the liver and other substances stored or processed by the liver can also be passed back into the blood 
(Wisse et al., 1996). 
Bile duct epithelial cells line the interlobular bile ducts within the portal triads (Strazzabosco and 
Fabris, 2008). 
Ito cells are found in the space of Disse.  They are important because when the liver is injured, the 
Ito cells transform into cells that produce collagen, which leads to liver fibrosis.  If this occurs on a 






    
Figure 1.2:  Schematic illustration of the structure of the liver lobule (Adapted from www. 









1.1.3      Liver functions 
The liver has 4 essential functions:   
1. Synthesis of many proteins that circulate in the blood. These include albumin, coagulation 
factors, alpha1-antitrypsin, very low density lipoprotein, and many others (David et al., 
2005).      
2. Stores nutrients for later use.  The liver balances the supply of nutrients with demand.  For 
example, the liver stores glucose as glycogen, and converts it back to glucose as needed.  If 
the supply of glycogen is depleted, the liver can also synthesize glucose from amino acids, 
lactate, and glycerol, although this is less efficient than breaking down glycogen into 
glucose.  Additionally, the liver metabolizes fatty acids, cholesterol, and amino acids.  
When there is a surplus of glucose in the bloodstream, the liver can convert excess glucose 
and amino acids into fatty acids for storage.  The liver both synthesizes cholesterol and 
removes it from circulation.  Finally, the liver can synthesize non-essential amino acids 
when needed by the body (David et al., 2005).   
3. Detoxification and elimination of toxic substances.  Toxins are detoxified by the liver‟s 
ability to metabolize lipophilic compounds.  These compounds (bound to albumin) enter the 
liver sinusoids and then the space of Disse.  Enzymes in the hepatocytes (cytochrome P-450 
enzymes) are involved in the metabolism of the lipophilic compounds, which include toxins 
and many drugs (David et al., 2005).    
4. Production of bile.  Bile acts as a detergent, and breaks fats down into smaller components 
so they can be digested in the small intestine.  Bile also provides a way for the liver to 
remove wastes, including bilirubin, cholesterol, and toxins.  Bile is formed in the biliary 
canaliculi, which drain into the interlobular bile ducts.  These ducts then merge with other 
ducts, forming larger intermediate ducts, which eventually merge into the right and left 
hepatic ducts, which themselves merge into the common hepatic duct, which merges with 
the cystic duct from the gallbladder, finally forming the common bile duct, which empties 
into the small intestine (David et al., 2005).    
Although, animal models cannot always predict human toxicities, however the frequency of drug 
toxicities described in clinical trials is not so thoroughly monitored and drug-induced toxicity is 
often detected long after a drug enters the market. The study was therefore carried out to mimic the 
therapeutic conditions of patients under antiretroviral therapy. 
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1.2      Pathophysiology and etiology of HIV/AIDS 
Human immunodeficiency virus replicates in CD4+ T cells and results in the depletion of cells 
which in turn is responsible for gradual decline in the T cell immunity. HIV viral replication results 
in the production of viral particles which are responsible for the development of chronic 
inflammation that contributes hugely to the disease pathogenesis and progression towards AIDS and 
death (Deeks, 2009). There are two distinct serotypes of HIV virus: type 1 and type 2. The HIV-1 is 
the primary cause of acquired immunodeficiency syndrome (AIDS) worldwide while, HIV-2 is 
found predominantly in West Africa and its vertical transmission develops more slowly and milder 
compared to HIV-1 (Sanders et al., 2007).  
Acquired immune deficiency (AIDS), is the late stage of HIV infection, a condition characterized 
by destruction of CD4+ T cells which help the body fight diseases (NASCOP, 2002). The syndrome 
was first identified in 1981 among homosexual men and intravenous drug users in New York and 
California and after its detection evidence of AIDS epidemics grew shortly after among 
heterosexual men, women, and children in sub-Saharan Africa (CDC, 2009). Although initial 
infection with HIV can result in flu-like symptoms, infected persons typically can show no 
symptoms for many years but as HIV replicate in the body, infected persons begin to show signs 
and symptoms of e.g., shingles, tuberculosis, oral or vaginal thrush, herpes simplex virus, and 
Kaposi sarcoma (WHO, 2009) which is a reflection of a weakened immune system or loss of the 
body‟s ability to fight infection.  
HIV works by encoding the enzyme reverse transcriptase and thereby making a DNA copy of the 
viral RNA, which can remain in the nucleus of the infected cell for a long time (Morris and Cilliers 
2008; Spencer, 2005). The virus attacks CD4 cells and macrophages and causing it to diminish in 
number thereby making the patients susceptible to opportunistic infections.  As a result CD4 cell 
count together with viral load is frequently used to assess HIV disease progression (Fenton and 
Silverman, 2008). The virus is most commonly transmitted via blood or semen during unprotected 
intercourse with an HIV-infected individual (Fenton and Silverman, 2008). However, sharing 
contaminated needles and injecting contaminated blood products are also both ways of transmitting 
HIV (Spencer et al., 2007). Other body fluids that contain blood, pre-seminal fluid, vaginal fluid 
and breast milk are also possible routes for transmission of the virus (Fenton and Silverman, 2008).  
Mother to child transmission of HIV is a major global concern and can occur before or during birth 
or through breast-feeding (Semba, 2006). 
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HIV infected population are prone to liver disease as evidenced from literatures. HIV infection by 
itself may contribute to hepatic and biliary tract abnormalities including hepatomegaly, liver 
fibrosis, liver cirrhosis, hepatic/biliary steatosis and elevated liver enzymes.  (Ramana et al., 2013). 
Co-infections with other hepatocellular viral infections like Hepatitis B virus and hepatitis C virus 
may further be responsible to liver related severe morbidity and mortality (Ramana, 2012).  
The impact of HIV has been most severe in some of the poorest countries in Africa. At the end of 
2009, there were 9 countries in Africa where more than one tenth of the adult population aged 15-49 
years was infected with HIV (UNAIDS, 2010). In the same year, an estimated 1.8 million new HIV 
infections occurred in Africa accounting for 69 percent of new infections worldwide and 370,000 
children began their lives with HIV (UNAIDS, 2010). Sub-Saharan Africa is more heavily affected 
by HIV and AIDS than any other region of the world. In 2008, it was home to two thirds (67%) of 
all people living with HIV and nearly three quarters (72%) of AIDS-related deaths (UNAIDS and 
WHO, 2009).    
As the HIV/AIDS pandemic continues to expand, the moral imperative to provide safe and 
efficacious treatment options becomes of paramount interest to the international health-care 
communities. The use of antiretroviral therapy (ART) has become the cornerstone of the clinical 
approach available to prevent transmission and slow progression of the infection in people living 
with HIV/AIDS (PLWHA) worldwide. Efforts have begun for a significant scaling up of the use of 
antiretroviral drugs (ARVs) in settings such as sub-Saharan Africa where the epidemic has had its 
most devastating impact. 
1.3      Management of HIV and AIDS- Antiretroviral therapy 
Antiretroviral therapy (ART) was developed for people living with HIV/AIDS (PLWHAs) to 
prolong life and reduced mortality and morbidity associated with AIDS. UNAIDS estimated that 
more than 2.5 million deaths have been averted since the introduction of antiretroviral therapy 
(UNAIDS, 2010). The main aim of ART is to suppress the plasma viral load and to restore the 
immune function. (NASCOP, 2002). This concurs with the fact that in the early 1980s when 
HIV/AIDS epidemic began and the corresponding absence of ART, people with AIDS were not 
likely to live longer than a few years (Carcelain et al., 1999).  
There has been increased expansion and access to ART to those eligible for treatment. 
Antiretroviral therapy coverage rose from 7% in 2003 to 42% in 2008, with especially high 
11 
 
coverage achieved in eastern and southern Africa (48%) (UNAIDS and WHO, 2009). According to 
UNAIDS and WHO estimates, 47% (6.6 million) of the estimated 14.2 million people eligible for 
treatment in low and middle-income countries were accessing life-saving antiretroviral therapy in 
2010, an increase of 1.35 million since 2009 (UNAIDS and WHO, 2010). In the eastern part of 
Africa, AIDS-related deaths have fallen by 29% since 2002, a decline which is attributed to the use 
of antiretroviral drugs (NACC and NASCOP, 2006).  
Today, there are more than 31 antiretroviral drugs grouped into five classes and approved by the  
U.S Food and Drug administration (FDA) to treat HIV infections (WHO, 2009 ). Each of the five 


















Table 1.1: Classes of ART and their mechanism of action. 
 






Inhibit reverse transcription by being incorporated into 








Inhibit reverse transcriptase directly by binding to the 
enzyme and interfering with its function.  
 
Protease Inhibitors  
(PIs)  
 
1995   
 
Target viral assembly by inhibiting protease enzyme used 
by HIV to cleave nascent proteins for final assembly of 
new virus. 
Fusion or Entry 




Prevent HIV from binding to or entering human immune 
cells. 
Integrase Inhibitors   
 
2007   
 
Inhibit integrase enzyme needed by HIV to insert its 
genetic material into human cells.   
Source: WHO (2009). 
1.4      Combination antiretroviral therapy (cART) 
However, conventional antiretroviral therapies (ARTs) do not completely eradicate HIV from the 
body and clinical trials are reporting that monotherapies are not completely effective (Saag and 
Kilby, 1999). Currently, preferred regimens use multi class combination product (involving 
combination of two or more antiretroviral therapy, an approach called highly active antiretroviral 
therapy (HAART) approved by the U.S Food and Drug Administration (FDA), which have resulted 
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in decreased HIV RNA levels and CD4 cell increases in the vast majority of patients (Saag and 
Kilby, 1999). With the advent of HAART, overall prognosis has improved dramatically with 
significant impact on the management of HIV infection, suppression of viral replication and 
reduction of the morbidity and mortality associated with AIDS (Palella et al., 1998). The advantage 
of HAART over monotherapy is a significant reduction in the risk of development of resistant 
strains commonly seen with monotherapy (Saag and Kilby, 1999). HAART has dramatically 
decreased the number of hospital admissions and AIDS patients have achieved an impressive 
improvement in the quality of life (Palella et al., 1998).  
1.4.1      HAART related liver toxicity 
While the use of HAART medications has had a profound impact on the AIDS epidemic in the 
world, it should be understood that the drugs carry their own side effects. Increasing adverse effects 
caused by HAART ranging from mild to severe have been well documented in many studies and are 
a major safety concern (Hawkins, 2010). Of late research has revealed that HIV infected individuals 
are at greater risks of developing non-infectious complications (Liver disease, cardiovascular 
disease that may precipitate with the initiation of HAART (Ramana et al., 2013). 
Hepatotoxicity, liver enzymes elevation and drug interactions are a significant problem in HIV 
patients on HAART.  Hepatotoxicity can influence HIV-1 treatment and can cause an increase in 
morbidity and mortality (Ramana et al., 2013). Protease Inhibitors (PIs), nucleoside reverse 
transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) can 
be hepatotoxic with asymptomatic elevations in liver enzymes, liver dysfunction and liver failure 
(Martinez, 2004). Hepatotoxicity related to NRTIs was first documented in the early 1990s with 
zidovudine monotherapy (Gradon et al., 1992). Combination therapy was subsequently found to 
further increase the risk of hepatotoxicity. Asymptomatic enzyme elevations greater than five times 
normal have been recorded in patients under HAART (Saves et al., 1998). 
The liver plays a central role in transforming and clearing of chemicals such as drugs and it is 
susceptible to damage from toxicity of these agents. Due to its unique metabolism and close 
relationship with the gastrointestinal tract, the liver receives blood coming directly from 
gastrointestinal organs and then spleen via portal veins which bring drugs and xenobiotics in near-
undiluted form (Sulkowski, 2004). Certain medicinal agents, when taken in overdoses and 
sometimes even when introduced within therapeutic ranges, may injure the liver causing them to be 
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withdrawn from the market due to hepatotoxicity (Sulkowski, 2004). The National Institutes of 
Health of USA presented findings on liver toxicity in International AIDS Society (IAS) conference 
and its retrospective analysis showed that hepatotoxicity is associated with all classes of 
antiretroviral medications in use (Clifford et al., 2003).  
Drug induced hepatotoxicity characterized by elevation of AST/ALT levels to at least twice the 
upper limit of normal (ULN) can occur with drugs from all ARV classes (Sulkowski et al., 2000).  
Several mechanisms are responsible for either inducing hepatic injury or worsening the damage 
process due to HAART.  Many chemicals damage mitochondria causing it to release excessive 
amount of oxidants which, in turn, injure hepatic cells releasing intracellular enzymes into blood 
circulation (Martinez, 2004). 
Although most liver diseases cause only mild symptoms initially, it is vital that early diagnosis and 
detection is done by performing full liver function tests (LFTs). Patients with HAART-induced 
hepatotoxicity may be asymptomatic, with liver injury diagnosed during routine blood testing, while 
others develop symptoms including nausea, fatigue, itching and jaundice  with the latter symptom 
being significant (O‟Brien et al., 2003). Liver function tests (LFTs) are carried out to detect the 
presence of liver disease, distinguish among different types of liver disorders, and gauge the extent 
of known liver damage and response to treatment (Prognosis) (Abrescia et al., 2005).  
 1.5      Liver function test (LFTs) 
LFTs are a group of clinical biochemistry laboratory blood assays designed to give information 
about the state of a patient's liver (Abrescia et al., 2005). Some liver analytes in LFTs are associated 
with liver functionality e.g. Albumin (ALB) and total proteins (PROT), others are concerned with 
hepatocellular integrity e.g. aminotransferases (ALT & AST) and some associated with cholestasis - 
biliary tract blockage e.g. gamma-glutamyl transferase (ɤ-GT) and alkaline phosphatase (ALP) 
(MoH, 2007). Liver biomarkers are useful in the monitoring, evaluation and management of 
patients with hepatic dysfunction due to drug toxicity (Abrescia et al., 2005). The most important 






1.5.1      Total protein (PROT)  
Plasma proteins are synthesized predominantly in the liver and are the building blocks of all cells 
and body tissues. In the course of disease PROT concentration and the percentage represented by 
individual fraction can significantly deviate from normal values (Koller, 1984). Total protein 
measurements are used in the diagnosis and treatment of a variety of diseases involving the liver 
(Lindsey, 1986).   
1.5.2      Albumin (ALB)   
Albumin is a carbohydrate-free protein, representing 55 to 65 percent of the plasma PROT. It 
maintains the plasma colloidal osmotic pressure, transport and stores a wide variety of ligands and 
serves as a source of endogenous amino acids. It binds toxic heavy metal ions and many drugs 
which is why a decrease in albumin in the blood can have important pharmacokinetic consequence 
(Grant et al., 1987). Hyperalbuminemia is of little diagnostic significance except in dehydration but 
hypoalbuminemia is very common in many diseases. It stems from various factors namely, impaired 
synthesis as a result of liver disease or due to diminished protein intake and increased catabolism 
due to tissue damage or inflammation (Grant et al., 1987).  An albumin measurement also allows 
for monitoring of the patient‟s response to nutritional support and is useful test of liver functionality 
(Marshal, 1989). In severe hypoalbuminemia, plasma albumin levels are below 25g/L (Grant et al., 
1987).   
1.5.3      Alanine aminotransferase (ALT)   
Alanine aminotransferase (ALT) is an enzyme present in a variety of tissues and its major source is 
the liver. Measurement of ALT levels is used in diagnosis of hepatic disease where elevated serum 
ALT is found in hepatitis, cirrhosis, obstructive jaundice, carcinoma of the liver, and chronic 
alcohol abuse (Sherwin and Sobenes, 1996). Both serum aspartate aminotransferase (AST) and 
ALT become elevated whenever disease processes affect liver cell integrity. Though ALT is liver 
specific and its activity persist longer than elevations of AST activity (Sherwin and Sobenes, 1996). 
Elevated ALT/AST above 40U/L is an indicator for hepatotoxicity which can be categorized as 
mild/grade 1 (40-84 U/L); moderate/grade 2 (85-174 U/L); severe/grade 3 (175-350U/L) and 




1.5.4      Aspartate aminotransferase (AST)  
Aspartate aminotransferase is widely distributed in tissue, principally hepatic, cardiac, muscle, and 
kidney and elevated serum levels are found in diseases affecting these tissues (Nagy, 1984).  
Hepatobiliary diseases such as cirrhosis, metastatic carcinoma, and viral hepatitis also increase 
serum AST levels (Nagy, 1984).      
1.5.5      Alkaline phosphatase (ALP)  
Alkaline phosphatase is a group of phosphatases found in almost every tissue in the body.  Normal 
adult males tend to have ALP higher levels than females, but pregnant females have increased 
levels due to placental secretion of ALP (Moss et al., 1987). Normal ALP levels are elevated during 
periods of active bone growth, like in young children and adolescents  however, abnormal elevation 
of ALP levels >160 U/L occurs in diseases such as hepatitis, cirrhosis, malignancy, chemical 
toxicity, and bone diseases such as metastatic carcinoma, rickets, Paget‟s disease, and osteomalacia 
(Moss et al., 1987).    
1.5.6      Gamma glutamyl transferase (GGT)  
Gamma glutamyl transferase is an enzyme involved in the transfer of γ-glutamyl residue from γ-
glutamyl peptides to amino acids, water and other small peptides. GGT activity is found primarily 
in brain, prostrate, pancreas and liver (Krefetz and McMillin, 2005).  Enzymatic activity of γ-GT is 
often the only parameter with increased values when testing for diseases affecting the mentioned 
organs and is one of the most sensitive indicators known (Krefetz and McMillin, 2005).  γ-GT 
activities are found in the serum of patients requiring long term medication with Phenobarbital and 
phenytoin (Krefetz and McMillin, 2005). Clinical applications of assay however are confined 
mainly to diagnosis and monitoring of hepatobiliary disease (Krefetz and McMillin, 2005). 
1.5.7      Total bilirubin (BIL-T)  
Bilirubin is formed in the reticulo-endothelial system during the degradation of aged erythrocytes. 
The heme portion from hemoglobin and from heme-containing proteins is removed, metabolized to 
bilirubin, conjugated with glucuronic acid for solubilization and subsequent transport through the 
bile duct and elimination via the digestive tract (Fody, 2005). Elevations of circulating 
unconjugated bilirubin occur in liver immaturity and several diseases, in which the bilirubin 
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conjugation is impaired causes.  Bile tract obstruction or damage to hepatocellular structure causes 
increase in levels of both direct and indirect bilirubin in the circulation (Balisteri and Shaw, 1987). 
As PLWHA continue to rely on HAART to enhance their quality of life, HAART-related toxicities 
keeps occurring and are encountered by clinicians (Campbell et al., 2009) and there is need to 
tackle this challenge. 
1.6       Interactions of HAART and plant-based extracts 
There has been a great deal of interest recently in the role of complementary and alternative 
medicines for the treatment of various acute and chronic diseases (Aruoma et al., 2006). Of the 
various classes of phytochemicals, interest has focused on the anti-inflammatory and antioxidant 
properties found in various plants extracts. Recently medicinal plants are being increasingly utilized 
to treat a wide variety of clinical diseases and numerous cultures still rely on indigenous medicinal 
plants for their primary health care needs (Gurib-Fakim et al., 2010). 
South Africa, a country with a strong history of traditional healing, hosts a variety of around 30,000 
flowering plant species, accounting for almost 10% of the world‟s higher medicinal plant species 
(Van Wyk, 2008). 
Reynolds et al., 2003 observed that access to effective therapies for HIV-positive persons is 
arguably one of the highest global public health priorities but while providing affordable access to 
PLWHAs, treatment should be accompanied with alternative therapy to enable patients live longer 
and healthier. These authors suggested that “the expansion of access to highly active antiretroviral 
therapy (HAART) should be accompanied by a more evidence-based approach to optimize HIV 
care guidelines locally” (Reynolds et al., 2003). 
Consequently, an enhanced appreciation of the potential interactions between HAART and plant-
based extracts will be critical for the promulgation of relevant evidence-based practice guidelines. 
The importance of this will be a distinguishing characteristic and may prove helpful in combating 
the disease course. Although consideration of the potential for herbal-drug interactions is most often 





1.7      Hypoxis hemerocallidea 
Hypoxis hemerocallidea (H. hemerocallidea) belongs to the genus Hypoxis, from the large lily 
family Hypoxidaceae and is widely distributed in the southern Africa sub-region (Boukes and van 
de Venter, 2011). The plant is characterized by strap like leaves, and bright yellow, star- shaped 
flowers (Musabayane et al., 2005).  The tuberous rootstock (i.e. the corm) of the plant is commonly 
referred to as „African potato‟ and is referred to in various local languages as Afrika patat 
(Afrikaans), inkomfe (Zulu) and ilabatheka (Xhosa) (Ojewole et al., 2009). There are over 90 
Hypoxis species spread throughout sub-Saharan Africa, North and Southern America, South East 
Asia, and Australia. Southern Africa holds a diversity of about 45 of these species (Drewes et al., 
2008).  
Taxonomically, the H. hemerocallidea plant falls under the star-lily family or Hypoxidaceae, which 
consists of 8 general and 130 species; with 90 of them belonging to Southern Africa (Drewes et al., 
2008).  
This family usually consists of monocotyledonous plants, which are normally found in the savanna 
regions of South Africa, Swaziland, Lesotho, Botswana, Mozambique, Zimbabwe and in North-
Eastern Africa (Drewes et al., 2008; Katerere and Eloff, 2008). In South Africa, H. hemerocallidea 
plant is found growing in the wild areas of the Eastern Cape, KwaZulu-Natal, Gauteng and 
Limpopo provinces. It can also be found in the mountainous areas of South America, Australia, and 
in the coasts of Asia (Drewes et al., 2008). 
 The H. hemerocallidea plant has been described as a stemless, geophytic, perennial herb with large 
dark brown to black corms (tubers) and bright yellow flowers; the plant is a herbaceous and a 
tuberous perennial plant that consists of yellow star-shaped flowers, long strap-like leaves (30 cm 
long and 3.2 cm wide), brown tuberous rhizomes or corms (up to 10 cm in diameter or length and 
about a half a kilogram in weight) and lots of adventitious roots that allow them to survive 
unfavorable conditions as shown in the figures 1.3 and 1.4 (Ndong et al., 2006). 
 Traditionally, after washing with clean water, the plant‟s corms are cut into small pieces, boiled for 
about 20mins, and then the decoction is consumed orally. H. hemerocallidea extracts, powders, 
infusions and decoctions have been used for centuries by southern African traditional healers for the 
treatment, management and control of an array of human ailments, including cancers, nervous 





Figure 1.3: Photograph showing the H. hemerocallidea plant (Drewes et al., 2008). 
 





1.7.1      Chemical constituents of Hypoxis hemerocallidea 
H. hemerocallidea corm has a catalogue of folkloric and therapeutic uses. It is one of the most 
popular and ethno-botanically acknowledged medicinal plants in southern Africa (Drewes et al., 
2008). Attempts have been made in some laboratories to isolate, purify and characterize the 
chemical constituents of this plant‟s corm that could be responsible for its medicinal properties. One 
of the most important chemical constituents of the herb which has been confirmed to be abundantly 
present in extracts of  H. hemerocallidea is a norlingan diglucoside, hypoxoside, a biologically 
inactive pro-drug (Nair and Kanfer, 2006), with an uncommon aglycone structure, consisting of 
diphenyl-1-en-4-yne-pentane skeleton (Nair et al., 2007). Hypoxoside is reported to have low 
toxicity, hence, the traditional consumption of „African potato‟ as a food (Smit et al., 1995). In 
human gut, hypoxoside is converted to rooperol, a biologically active compound, by 
betaglucosidase enzyme, which is abundantly present in the human gut and rapidly dividing cancer 
cells (Mills et al., 2005). 
Both rooperol and its pro-drug, hypoxoside, have been shown to undergo phase 1 hepatic 
metabolism by cytochrome P450 (probably CYP 3A4) enzyme, while their phase II metabolic 
products, consisting of diglucuronide, disulphate and mixed glucuronide-sulphates, are eliminated 
by first-order kinetics (Mills et al., 2005). Rooperol can be recovered from these metabolites by 
deconjugation reactions (Albrecht et al., 1995). Most of the therapeutic properties of H. 
hemerocallidea extracts observed clinically in man and in laboratory animals to date have been 
attributed to rooperol (Albrecht et al., 1995).  
Rooperol has been shown to be antineoplastic, bacteriostatic and bactericidal (Drewes et al., 2008). 
It has been suggested that the antimetastatic activity of rooperol could be mediated through its 
ability to stimulate the synthesis of collagen type 1 that could impede cell invasions (Dietzsch et al., 
1999).  Recent laboratory investigations have shown that rooperol has a strong antioxidant activity, 
a strong affinity for phospholipid membranes, and that it inhibits free radical-induced membrane 
lipo-oxidation (Laporta et al., 2007). These findings seem to suggest that rooperol is important in 
the maintenance of cell membrane stability (Hostetmann et al., 2000), a phenomenon which 
partially explain its activity against neoplastic cells. It is still unclear at the moment, whether the 
ability of rooperol to inhibit inflammatory processes in vitro and in vivo, is as a consequence of its 
direct ability to inhibit the production of pro-inflammatory cytokines, tumour necrosis factor (TNF)-
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α, and interleukins; or due to its inhibitory effects on enzymes involved in the synthesis of pro-
inflammatory mediators, such as leukotrienes and prostaglandins (Hostetmann et al., 2000). 
In a study, Van der Merwe et al., (1993) showed that rooperol is a potent inhibitor of lipo-
oxygenase (an enzyme that catalyses the first-step in the conversion of arachidonic acid to 
leukotrienes), but not cyclooxygenase (COX), which catalyses the rate-limiting step in the 
conversion of arachidonic acid to prostaglandins. Another study by Guzek et al., (1996), in an 
investigation which attempted to highlight the potential therapeutic benefit of H. hemerocallidea 
extracts in the treatment of airways inflammatory diseases, showed that rooperol and its derivatives 
inhibit the production of TNF-α, interleukin1-β and interleukin-6, and also suppress the production 
of nitric oxide in vitro. However, direct inhibitions of COX-1 (constitutive) and COX-2 (inducible) 
isoforms of the COX enzymes by extracts of H. hemerocallidea corm have also recently been 
reported (Gaidamashivili and Van Staden, 2006).  
Despite the prevailing uncertainties about the precise mechanisms by which rooperol exerts its anti-
inflammatory effects, it is important to recognize that rooperol shares intimate structural similarity 
with a well-known, strong antioxidant, nordihydroguairectic acid (Nair et al., 2007), and 
comparably inhibits leukotriene and prostaglandins synthesis in polymorphonuclear  leukocyte and 
platelet microsomes, respectively (Coetzee et al., 1996).  
On the strength of the available scientific, pharmacological and clinical evidence, several patents 
have been registered on rooperol, and the extract has also been registered under the trade name 
„HarzolTM‟ in Germany for the treatment of prostate cancer (Nair et al., 2007). At present, there are 
numerous commercial herbal preparations which contain rooperol or extracts of H. hemerocallidea 
in the market for the treatment, management and control of many modern and 21st century diseases 
of man (Nair et al., 2007). 
Among the chemical constituents of H. hemerocallidea, phytosterols have been suggested to be 
partly responsible for some of the observed therapeutic and pharmacological properties of the 
corm‟s extracts. Mohamed and Ojewole (2003) attributed the hypoglycaemic effect of H. 
hemerocallidea extracts observed in streptozotocin induced diabetic rats to phytosterols and 
sterolins. Phytosterols are known to stabilize plant cell membranes (Nair and Kanfer, 2006), and are 
also known to have many therapeutic benefits, including enhancement of immune system in 
immune-compromised individuals (Laporta et al., 2007). The antiprostatic adenoma activity 
attributed to extracts of H. hemerocallidea, has also been ascribed to phytosterol glycosides, mainly 
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β-sitosterol glycosides (Hostetmann et al., 2000). These claims, however, remain speculative in 
view of the fact that daily intake of the same amounts of phytosterols and their glycosides from 
other plant sources have not produced the same magnitude of therapeutic effects (Hotelman et al., 
2000). 
1.7.2      Pharmacological properties of Hypoxis hemerocallidea 
In recent years, attempts have been made to investigate the scientific basis of the therapeutic claims 
attributed to H. hemerocallidea. Evidence-based laboratory investigations indicate that aqueous and 
alcohol extracts of H. hemerocallidea possess many interesting pharmacological properties, 
including anti-nociceptive (in mice), anti-inflammatory and anti-diabetic properties (in rats) in vivo 
(Ojewole, 2006). „Intraperitoneal injections of 50-800 mg/kg body weight of H. hemerocallidea 
extracts produced significant and dose-dependent anti-nociceptive effects against chemically- and 
thermally-induced nociceptive pain in mice‟ (Ojewole, 2006). At the same dose level, oral 
administrations of H. hemerocallidea corm extract also „significantly inhibited egg albumin-induced 
acute inflammation and streptozotocin-induced diabetic rats in a dose-dependent manner‟ (Ojewole, 
2006). These observations, therefore, suggest that extracts of H. hemerocallidea could possess anti-
inflammatory and anti-diabetic (hypoglycaemic) properties respectively.  
As suggested by Ojewole (2006), the extracts of H. hemerocallidea could inhibit the synthesis, 
production and release of inflammatory cytokines and mediators such as prostaglandins. Studies 
have also indicated that lectin-like proteins purified from aqueous extracts of H. hemerocallidea can 
inhibit cyclooxygenase (COX) enzyme that mediates prostaglandins synthesis in vitro 
(Gaidamashivili and Van Staden, 2006). However, other studies have shown that ethanol extracts of 
H. hemerocallidea have higher inhibitory effects on COX-1 catalysed prostaglandin synthesis than 
aqueous extracts of the plant‟s corms (Steenkamp et al., 2006). Aqueous extracts of H. 
hemerocallidea corms have previously been shown to scavenge free radicals (hydroxyl ions) in 
vitro (Mahomed and Ojewole, 2003), and it has been suggested that the ability of the corm‟s 
extracts (both aqueous and ethanol) to suppress inflammation could be mediated via its antioxidant 
activity which in turn, inhibits COX enzymes (Steenkamp et al., 2006).  
It has also been reported that lectin-like proteins derived from extracts of H. hemerocallidea 
inhibited the growth of Staphylococus aureus, in vitro (Gaidamashivili and Van Staden, 2002). 
Undoubtedly, agglutinins found in the storage parts (corms) of H. hemerocallidea, play a critical 
role in the plant‟s defensive mechanism against pathogenic micro-organisms. This observation 
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would, therefore, support the age-old usage of H. hemerocallidea in the treatment of microbial 
infective disorders (Hutchings et al., 1996; Laporta et al., 2007).  
Laboratory reports have further shown that both ethanol and aqueous extracts of H. hemerocallidea 
corm inhibit the growth of Escherichia coli, in vitro (Steenkamp et al., 2006), an observation quite 
consistent with the previously reported antibacterial activity of H. hemerocallidea (Gaidamashivili 
and Van Staden, 2002). Escherichia coli infection is the most common secondary cause of bacterial 
prostatitis (Steenkamp et al., 2006). This observation may therefore, partly also explain the 
traditional usage of the extracts of this plant‟s corm in the treatment of urinary tract infections 
(Singh, 1999). Benign prostate hyperplasia (BPH) can cause blockade of the urinary tract in men, 
and this may lead to chronic bacterial prostatitis. Anecdotal and folkloric reports have documented 
that H. hemerocallidea extracts have been used traditionally in the treatment of prostate hyperplasia 
(Singh, 1999). The observation that H. hemerocallidea extracts can inhibit the growth of E.coli in 
vitro, therefore, seems to support the use of this plant‟s corm in the treatment of prostate 
hyperplasia.  
However, more recent experimental and clinical evidence have suggested that the effects of H. 
hemerocallidea corm extracts on BPH might not only be due to their antibacterial activities, but 
could also be due to their anti-inflammatory and antioxidant properties (Ojewole, 2002). This body 
of evidence, therefore, supports the claims that H. hemerocallidea extracts may contain chemical 
compounds that suppress tumour growth, and hence, its use in the treatment of cancers (Nair et al., 
2007).  
It has also been reported that aqueous extracts of H. hemerocallidea caused bradycardia and brief 
hypotension in guinea-pigs and rats in vitro and in vivo, respectively (Ojewole et al., 2006). 
Although the investigators were unable to establish the precise pharmacological mechanisms 
underlying their observations, they ruled out involvement of the cholinergic system, since the 
cardio-depressant effects of the extracts were not modified by atropine pretreatment (Ojewole et al., 
2006).  However in a study involving Chacma baboons, Coetzee et al., (1996) established that a 
purified extract of H. hemerocallidea corms (rooperol) increased myocardial contractility in vivo. 
Rooperol caused moderate, transient increased cardiac output, stroke volume and vascular pressures 
without increased heart rate or filling pressures, suggestive of increased myocardial contractility 
probably allied to its catechol structure (Coetzee et al., 1996).  
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 The cardiovascular observations tend to suggest that extracts of H. hemerocallidea corm contain 
some bioactive chemical compounds with cardiovascular activities. These findings may also lend 
pharmacological credence to the age-old usage of this plant in the treatment and management of 
heart ailments and hypertension in some rural communities of southern Africa. 
However, what has recently stimulated the greatest interest, not only among traditional healers and 
their patients, but also in scientific communities, the pharmaceutical industries as well as in 
government circles, is the claim that H. hemerocallidea corm can boost human immune system. 
Some healthcare providers in South Africa are currently using extracts of H. hemerocallidea corms 
as immune-stimulant preparations for patients living with HIV/AIDS, on the strength of the 
recommendation of South Africa‟s national Department of Health (Southern Africa Development 
Community, 2002; Mills et al., 2005).  
In this regard, the use of this plant‟s corms has been extended to immune-related illnesses, such as 
common cold, flu and arthritis (Mills et al., 2005). Unfortunately, despite the popular belief in the 
immune-boosting properties of this plant‟s corms, there is absolutely no laboratory or clinical 
evidence yet to support this immune-stimulant claim, which at present still remains speculative. 
1.8      Statement of research problem 
The goals of HAART include achieving and maintaining viral suppression, improving immune 
function and delaying disease progression. This has led to improved wellbeing and longevity of 
people living with HIV/AIDS (PLWHAs) (Tomkins, 2005). However, adverse effects have 
been associated with this chemotherapeutic regime for PLWHAs (Charles et al., 2014). For 
instance, hepatotoxicity has been reported in most antiretroviral drugs contributing to more than 
50% of acute liver failure cases, a fraction of which require immediate transplantation (d‟Arminio et 
al., 2000).  
These adverse effects can lead to non-adherence and interruption or discontinuation of HAART 
which increases risk for cardiovascular disease, hepatic complications, opportunistic infections and 
eventually death (Nerad et al., 2003, Hammer et al., 2008, Stein, 2009). The hepatotoxicity 
associated with HAART, complicates its management and increases the cost of overall health care 
making it a double edged sword. 
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It is anticipated that as the population of PLWHAs remain on HAART for longer period of 
time, HAART-related metabolic disorders would correspondingly increase. The 
consequences are quite huge in terms of economic cost and care. Jevtovic (2008) observed 
that the cumulative long-term toxicities of HAART emerge as a significant complication to the 
liver. 
 
These adverse effects associated with using HAART for the treatment of HIV infection have further 
encouraged the utilization of herbal medicines as an alternative medical therapy by PLWHAs 
(Gurib-Fakim et al., 2006). This complementary or alternative therapy is thought to mitigate this 
toxic effect of HAART regimens (Gurib-Fakim et al, 2006).  
1.9      Research questions 
i. Does H. hemerocallidea mitigate liver injuries following HAART? 
ii. Would vitamins C and E serve as a better antioxidant supplements in HAART-induced liver 
injuries? 
iii. Does liver function tests (LFTs) reveal information on the liver following HAART and H. 
hemerocallidea? 
1.10      Objectives of study 
The objectives of this study are presented in line with three major focus areas: 
a. To determine the histological effects of highly active antiretroviral therapy on the liver of 
experimental animals. 
b. To determine the effect of co-administration of crude aqueous extract of Hypoxis 
hemerocallidea and highly active antiretroviral therapy on the liver of experimental 
animals.  
c. To assess the changes in liver enzymes in HAART treatment alone and co-administration of 
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Abstract 
As the roll-out of antiretroviral therapy continues to drive downwards morbidity and mortality in 
PLWHAs, organ toxicities (especially the liver) are frequently becoming a major concern for 
researchers, scientists and healthcare planners.  
This study was conducted to investigate the possible protective effect of Hypoxis hemerocallidea 
(H. hemerocallidea) against HAART-induced hepatotoxicity. A total of 63 pathogen-free adult male 
Sprague-Dawley rats were divided into 9 groups and treated according to protocols.  
While no mortality was reported, animals treated with adjuvant HAART and H. hemerocallidea 
recorded least %body weight gain. Significant derangements in serum lipid profiles were 
exacerbated by treatment of with H. hemerocallidea as LDL (increased p<0.03), TG (increased 
p<0.03) with no change in total cholesterol levels. Adjuvant H. hemerocallidea with HAART 
recorded reduced LDL (p<0.05 and 0.03), increased HDL (p<0.05) and TG (p<0.05 and 0.001). 
Markers  of liver injury assayed showed significant increase (p<0.003, 0.001) in AST in H. 
hemerocallidea alone as well as HAART+ vitamins C and E groups respectively. Adjuvant HAART 
and H. hemerocallidea and vitamins C and E also caused significant declines in ALT and ALP 
levels. Serum GGT were not markedly altered. Histopathological derangements ranged from severe 
hepatocellular distortions, necrosis and massive fibrosis following co-treatment of HAART with 
vitamins C and E as well as HAART alone. These results warrant caution on the adjuvant use of H. 
hemerocallidea with HAART by PLWHAs as implications for hepatocellular injuries are suspect 




The acquired immune-deficiency syndrome (AIDS) is a significant threat to the health of mankind 
and the search for effective therapies to treat AIDS is of paramount importance. The development 
and evolution of anti-human immune deficiency virus (HIV), which causes AIDS has tremendously 
improved over the last 2 decades with resultant significant increase in life expectancy among HIV-
infected patients (Azu, 2012; Charles et al., 2014). Highly active antiretroviral therapy (HAART), a 
combination of this chemotherapeutic regime for people living with HIV/AIDS (PLWHAs), 
suppresses viral replication but its major drawback is adverse effects of toxicities to organs (Charles 
et al., 2014). 
 Hepatotoxicity has been associated with most antiretroviral drugs like zidovudine, stavudine or 
didanosine (Abrescia et al., 2005). The liver functions in the formation of excretory products, the 
degradation of complex cellular materials, and the synthesis of plasma proteins. Because of this 
functional complexity, any change in liver function and histoarchitecture, becomes an important 
consideration for study of abnormality (Soriano et al, 2008). 
Besides the high cost of HAART regimens, the adverse effects associated with using chemotherapy 
for the treatment of HIV infection have further encouraged the utilization of herbal medicines as an 
alternative medical therapy by PLWHAs (Ji et al., 2001). This complementary or alternative 
therapy is thought to mitigate this toxic effect of HAART regimens (Gurib-Fakim et al, 2010).  
Hypoxis hemerocallidea (H. hemerocallidea) commonly called African potato has a long history of 
traditional use for a diversity of ailments (Drewes et al, 1984) and more recently has been the 
subject of several scientific studies. In many parts of Africa the corms of this attractive yellow 
flowered herb have been used in the treatment of urinary diseases, prostate hypertrophy, and 
internal cancer (Nair et al, 2007) and more recently as immune boosters for HIV-AIDS. Its 
traditional usage dates back many generations (Awad and Fink, 2000) and anecdotal evidence 
indictaes that the plant can be poisonous (Arnold et al, 2000).  H. hemerocallidea is noted for the 
occurrence of a hypoxoside which is a secondary metabolite of the plant (Nair et al, 2007) that is 
hydrolyzed into rooperol-the active and powerful antioxidant component of the corm (Laporta et al, 
2007) in the large intestine.  
Pharmacokinetic studies have indicated that rooperol can be found in feces, and metabolites are 
found in the serum and urine as its glycosides, sulfates, mixed glucuronides, and sulfuronides 
(Kruger et al, 1994). These metabolites, when conjugated back to rooperol, were found to be 
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cytotoxic to cancerous cells (Nair et al, 2007). The glycoside has low toxicity and the corm 
containing it is also used as food (Drewes et al, 1984) and has been well used for traditional and 
pharmaceutical purposes (Awad and Fink, 2000).  
With increasing interest in the use of phytosterols (one of phytochemical components of H. 
hemerocallidea) for the reduction of serum cholesterol and for immune boosting, there has been a 
resultant increase in scientific investigations (Moreau et al, 2002) surrounding these benefits. 
Interestingly, there has been a surge in commercially available herbal medicines containing sterols 
with H. hemerocallidea extract enrichments claimed to be efficacious against a variety of diseases. 
However, the scientific validation of these claims remains to be verified despite its anti-
inflammatory, antimicrobial, antidiabetic, anticonvulsant and anticancer properties reported by 
various authors (Ncube et al, 2011; Ojewole et al, 2006; Steenkamp et al, 2006) but none on any 
antiretroviral based therapy. As a result, there is paucity of literature explaining its attenuating 
influence on the liver associated with HAART.  
Therefore, this work is aimed at investigating the role of crude aqueous extracts of H. 
hemerocallidea in the histoarchitecture of the liver, glycogen distribution, degree of fibrosis and 
hepatocellular functional indices of animal experimental protocol following highly active 
antiretroviral therapy. 
Materials and methods 
Chemicals and drugs  
Lamivudine (3TC), Stavudine and Nevirapine (Aspen) and vitamin C (L-ascorbic acid) were 
procured from Pharmacare Ltd, Port Elizabeth, South Africa and are of analytical grade. Vitamin E 
solution was obtained from Kyron Prescription CC, Benrose in Johannesburg. 
Plant  
Fresh corms of H. hemerocallidea were purchased from a local „Muthi‟ shop in Umbilo Road, 
Durban, KwaZulu-Natal, between June and July, 2014. The corms were authenticated at the 





Preparation of corm aqueous extract  
H. hemerocallidea fresh corms were extracted according to the procedure of Ojewole et al, 2009. 
They were washed with water, cut into smaller pieces, air dried at room temperature (25-280C) and 
ground into powdered form in a commercial blender. The milled corm was soaked in hot distilled 
water and extracted twice, on each occasion with 2.5 liters of hot distilled water (at 90–1000C) for 
12 hours. The combined extract soluble were concentrated to dryness under reduced pressure in a 
rotary evaporator at 70 ± 10C. The resulting crude aqueous extract was freeze dried, finally giving 
of a dark brown, and powdery aqueous extract residue. Without any further purification, aliquot 
portions of the aqueous extract residue were weighed and dissolved in distilled water (at room 
temperature) for use on each day of our experiments. 
Ethical approval 
The study protocol was approved by the University of KwaZulu Natal Animal Ethics Committee 
(Ethical clearance number: 100/14/Animals). The animals received humane care in accordance with 
the Principle of Laboratory Animal Care of the National Medical Research Council and the Guide 
for the Care and Use of Laboratory Animals of the National Academy of Sciences (National 
Institute of Health Guide, 1985). 
Animal treatment and experimental design 
Sixty three adult male Sprague-Dawley rats aged 9-10 weeks old and weighing between 256-312g 
were used for this study. The animals were bred and maintained at the Animal House of the 
Biomedical Resources Unit, University of KwaZulu-Natal. All the rats were housed in well 
ventilated plastic cages (7 animals per cage) having dimensions of (52cm long × 36cm wide and 
24cm high). They were maintained under standardized animal house conditions (temperature: 21–
23°C; light: approximately 12 h light per day) and were fed with standard rat pellets (from Meadow 
feeds a Division of Astral Operations Limited, Durban, South Africa) and given tap water ad 
libitum.  The animals were randomly distributed to nine treatment groups: A, B, C, D, E, F, G, H 
and I with seven animals per group and treated as follows: 
Group A: HAART (a cocktail of Lamivudine, Stavudine and Nevirapine) using recommended 
human therapeutic doses and accordingly adjusted to the equivalent animal dose was administered 
as a daily dose. 
Group B: received HAART and H. hemerocallidea (100 mg/kg body weight) 
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Group C received HAART and H. hemerocallidea (200 mg/kg body weight)   
Group D received HAART and Vitamin C (250 mg/kg body weight) 
Group E received HAART and Vitamin E 40 mg/kg body weight (Bansal et al., 2005)  
Group F: Combination of HAART, Vitamins C and E. 
Groups G and H received H. hemerocallidea extract alone at doses of 100 and 200 mg/kg 
respectively. 
Groups I served as the control administered 0.9% normal saline. 
All administration was done daily by oro-gastric gavage except for vitamin E which was 
administered subcutaneously. At the end of the treatment period (56 days), the animals were killed 
24 hours after the last treatment under excess Halothane ® anesthesia. 
Body and Liver weight 
Body weights of animals were recorded on the first day before treatment (initial), thereafter weekly 
and on the day of sacrifice (final). Liver weight (LW) was measured by an electronic balance 
(Mettler Toledo; Microsep (Pty) Ltd, Greifensee, Switzerland).  
Assessment of Liver function and lipid profile 
Blood samples were collected through cardiac puncture and allowed to cloth for 30 minutes and 
centrifuged for 15 minutes at 3000 revolutions per minute. The serum was decanted into Eppendorf 
tubes and prepared for biochemical analyses. 
Biochemical analyses of the serum enzymes for alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) were 
spectrophotometrically determined by the method of Reitman and Frankel (1957). 
Determination of Serum Lipids 
Low density lipoprotein (LDL), high density lipoprotein (HDL), Triglycerides (TG) and total 
cholesterol (CHOL) were determined by enzymatic methods according to Diniz et al., (2006) using 
commercial diagnostic kits (Randox, UK). 
Histopathological examination of liver tissues 
Twenty four hour after the last treatment the animals were given humane sacrifice under excess 
Halothane® anesthesia and the liver were removed and weighed. They were examined for gross 
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pathology and immediately fixed in 10% neutral buffered formalin. After proper fixation, the tissues 
were dehydrated in graded series of alcohol, cleared in Xylene and embedded in paraffin wax using 
a cassette.  
For routine histological study, the liver tissues were sectioned at 5µm thickness using Leica RM 
2255 microtome and stained with hematoxylin and eosin (H&E) for general assessment of liver 
structure. For histochemical studies, the tissues were stained with Periodic acid Schiff (PAS) for 
glycogen, neutral polysaccharides and basement membrane, and Masson trichrome (MT) for the 
assessment of possible fibrosis in the liver (John and Marilyn, 2007). The stained slides were then 
cover slipped using DPX mounting glue directly over the tissue section ensuring no air bubbles 
were trapped. Thereafter, the slides were left overnight to dry for examination under light 
microscope. 
The sections were examined using a binocular microscope, Nikon Eclipse 80i, Tokyo, Japan (used 
to acquire the images). An independent histopathologist blinded to the treatment groups reported on 
the qualitative assessments of the slides. 
Statistical analysis  
Continuous variables (Liver and body weights, Liver function test and Lipid profile level), were 
analyzed by one–way analysis of variance (ANOVA) followed by Dunnett‟s multiple comparison 
post-test using Graph pad prism ® statistical software 6.02. The results are expressed as mean ± SD 
(standard deviation). Values were considered significant at p <0.05. 
Results 
Mortality:  
No animal died during the experimental period. 
Body weight and organ (Liver) weight changes 
While the final body weights of rats were in all groups higher than their corresponding initial body 
weight, the percentage weight gain was maximal in group F (HAART with vitamins C and E), then 
groups A and I and B all recording 48.66 %, 46.38 % and 44.08 %, 42.48% respectively. Least 
weight gain was observed in group D animals treated with HAART and vitamin C (29.89%) (Table 
3.1). Similarly, liver weight changes were not statistically significant except for group B that 
recorded a slight increase (p<0.05) and group F that recorded lowest weight when compared with 
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the control. Organ-body weight ratios were significantly decreased in groups D, E, F, G and H 
(p<0.05) (Table 1). 
Table 1: Body and liver weight changes in experimental and control groups of animals 
GROUP Initial (g) Final (g) BW diff (g) % BW diff LW (g) LBWR 
A 260.00±6.06 381.00±11.21 121·00 46·38 12.83±1.31 0.035 
B 285.86±3.80 407.29±13.69 121·43 42·48 13.78±1.06 0.036 
C 311.43±3.56 427.00±09.94 115·57 37·11 14.18±3.41 0.035 
D 279.57± .16 363.14±11.50** 83·57 29·89 12.05±1.49 0.028* 
E 281.57±2.88 382.71±05.51 101·14 35·92 10.05±0.98* 0.028* 
F 261.00±7.49 388.00±08.28 127·00 48·66 10.08±0.76* 0.026** 
G 271.57±7.14 359.71±12.31** 88·14 32·46 10.66±0.72* 0.027* 
H 273.00±6.29 371.86±18.43* 98·86 36·21 09.41±1.27** 0.026** 
I 256.71±8.65 369.86±12.66* 113·15 44·08 13.16±2.38 0.035 
*p<0.05, **p<0.03, BW= body weight of rats, LW= liver weight of rats, LBWR= liver- body 
weight ratio. 
Serum AST, ALT, ALP and GGT in experimental groups 
There were changes in the functional hepatotoxicity indices recorded via AST, ALT ALP and GGT. 
Though AST levels were higher in all groups except A and E, it was significantly elevated in groups 
F and H (HAART with vitamin C&E and H. hemerocallidea 200mg/kg) respectively (p<0.001, 
0.03) compared with the control. There was statistically significant decrease in ALT levels in 
groups A, B, C, D and E (p<0.03) whereas the levels in groups F, G and H were lower than that of 
control (p>0.05). Similarly, ALP levels of animals treated with HAART, HAART + H. 
hemerocallidea (both doses), and HAART + vitamin E (p<0.001), HAART + vitamin C, H. 
hemerocallidea (both doses) (p<0.03) were significantly lower compared with the control. The 
results of the GGT levels were not statistically significant in all groups when compared with the 






Table 2: Effect on Serum AST, ALT ALP and GGT in the experimental and control group of 
animals 
GROUP AST (IU/L) ALT (IU/L) AST/ALT 
Ratio 
ALP (IU/L) GGT 
(IU/L) 
A 92.00±3.23 48.67±11.91*** 1.89 116.67±41.55*** 2.00±0.89 
B 106.33±7.45 52.00±2.37*** 2.04 95.00 ± 5.59*** 3.00±0.00 
C 108.00±9.30 51.33±8.96*** 2.10 88.00 ± 4.98*** 3.00±0.89 
D 104.67±4.03 55.33±7.61*** 1.89 122.67 ±16.79** 3.33±0.52 
E 94.33±13.55 44.00±3.10*** 2.14 99.67 ± 4.03*** 3.00±0.89 
F 128.33±6.83*** 75.67±17.6 1.70 167.00 ± 5.87 2.67±0.52 
G 105.33±11.67 75.00±8.53 1.40 160.67 ± 36.88* 3.00±0.89 
H 116.00±13.00** 75.67±8.31 1.53 145.33 ± 23.62** 2.67±1.37 
I 96.33±9.48 79.67±9.97 1.21 218.00 ± 71.52 2.33±0.52 
*p<0.05, **p<0.03, ***p<0.001, AST=alanine amino aspartate, ALT= alanine aminotransferase, 
ALP=alkaline phosphatase, GGT=gamma-glutamyl transferase. 
Effect on lipid profile 
Although there was marginal upward difference in total cholesterol levels in all groups, these were 
not significantly different (p>0.05). There were statistically significant increase in the serum levels 
of LDL in groups F and H (p<0.03), whereas groups treated with HAART, HAART + vitamin C 
(p<0.001), HAART + H. hemerocallidea 100mg/kg, HAART + vitamin E (p<0.05) as well as 
HAART + H. hemerocallidea 200mg/kg (p<0.03) all recorded significant decline in the parameter 
compared with the controls. HDL levels in groups A, C, E (p<0.05) as well as in groups D, F and H 
(p<0.03) were all significantly lower than the control group. While triglyceride (TG) levels in 
groups A, C, D, E (p<0.001), B (p<0.05) statistically declined, levels were however increased in the 
groups administered HAART + vitamins C and E (p<0.001) as well as H. hemerocallidea 200mg/kg 






Table 3: Lipid profile of the experimental and control groups of animals 
GROUP LDL (mmol/L) HDL (mmol/L) CHOL (mmol/L) TG (mmol/L) 
A -0.10 ± 0.02*** 1.00 ± 0.05* 1.10 ± 0.09 0.45 ± 0.09*** 
B -0.23 ± 0.13* 0.94 ± 0.06 1.07 ± 0.14 0.68 ± 0.16* 
C -0.12 ± 0.09** 0.98 ± 0.03* 1.10 ± 0.09 0.52 ± 0.13*** 
D -0.09 ± 0.06*** 1.04 ± 0.11** 1.17 ± 0.14 0.45 ± 0.14*** 
E -0.17 ± 0.03* 0.97 ± 0.05* 1.03 ± 0.05 0.51 ± 0.04*** 
F -0.62 ± 0.01** 1.06 ± 0.05** 1.13 ± 0.05 1.50 ± 0.04*** 
G -0.27 ± 0.03 0.92 ± 0.05 1.07 ± 0.05 0.90 ± 0.01 
H -0.63 ± 0.13** 1.06 ± 0.06** 1.07 ± 0.05 1.39 ± 0.30** 
I -0.38 ± 0.17 0.67 ± 0.47 1.03 ± 0.14 1.03 ± 0.23 
*p<0.05, **p<0.03, ***p<0.001. LDL=low density lipoprotein, HDL=high density lipoprotein, 
CHOL=total cholesterol, TG=triglycerides. 
Histopathology of the liver 
Whilst various stains were deployed to investigate qualitative changes in the liver, our report will be 
described according to the staining technique. In H&E stained slides, control sections of liver 
showed typical hepatocellular architecture with central vein (containing blood) and cords of 
hepatocytes arranged peripherally in a radiating fashion. The outlines of hepatocytes and sinusoidal 
spaces are clearly seen with no obvious pathologies. This trend was observed in liver sections from 
groups E (HAART + vitamin E). Histopathological assessment of other groups revealed various 
degrees of distortions. Liver tissues of group B animals showed mild distortion in the radial 
arrangements of hepatocytes and sinusoids with some form of ballooning of hepatocytes. Whereas 
in group C rats, some of the central veins appeared eroded with gradual loss of polyhedral 
arrangement of cords of cells. There was extensive necrosis of hepatocytes and sinusoidal spaces 
with marked loss of architecture in group D sections of liver. Some of the hepatocyte nuclei 
appeared enlarged. In sections of liver of group F animals, there was complete loss of architecture 
with hepatocytes appearing as isolated cell with (or without) prominent nucleoli. Groups treated 
with H. hemerocallidea alone (both doses) showed liver sections that generally appeared enlarged 
in sinusoidal appearance with necrotic distortions (Plates 1). 
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Photomicrograph of the liver sections stained with PAS reveal normal liver architecture, containing 
a large amount of glycogen with bright pink hepatocytes, neutral polysaccharides and basement 
membranes in the sections of animals treated with HAART + H. hemerocallidea (both doses), with 
vitamin C and E (Plates 2 A, D, E, F, G, H & I). The PAS stain demonstrates glycogen. However, 
there was distortion of hepatocellular cord in the animals administered with HAART and 
concomitantly with H. hemerocallidea (both doses) (Plates 2 B &C). 
Photomicrograph of the liver sections stained with Masson Trichrome (MT), show normal 
architecture of the liver stained blue while the cytoplasm of hepatocytes are stained red, nuclei can 
be seen as dark red to black structures within cells (Plates 3 A, E, F, G, H & I). Also, the liver 
sections showing fibrous tissue, as it is evident, the normal architecture of the liver is destroyed in 
this animals administered with HAART concomitantly with H. hemerocallidea (both doses), 

















Plates 1 (A): Photomicrograph of cross section of liver of Sprague-Dawley 
rats treated with HAART cocktail.  H & E stains. Note the swollen of the 

















Plates 1 (B): Photomicrograph of cross section of liver of Sprague-Dawley rats 
treated with HAART and low dose of H. hemerocallidea extract.  H & E 
stains. Note the cellular distortion of the hepatocytes of and the occlusion of 












Plates 1 (C): Photomicrograph of cross section of liver of Sprague-Dawley rats 
treated with HAART and high dose of H. hemerocallidea extract.  H & E 
stains. Note the disorganisation of the stellate cells and sinusoids and 













Plates 1 (D): Photomicrograph of cross section of liver of Sprague-Dawley 
rats treated with HAART and vitamin C.  H & E stains. Note the displacement 













Plates 1 (E): Photomicrograph of cross section of liver of Sprague-Dawley rats 
treated with HAART and vitamin E.  H & E stains. Note the disorganisations 












Plates 1 (F): Photomicrograph of cross section of liver of Sprague-Dawley rats 
treated with HAART and vitamin (C and E).  H & E stains. Note the  cellular 
distortions of the sinusoidial cells and stellate cells and hyperplasia of the 














Plates 1 (G): Photomicrograph of cross section of liver of Sprague-Dawley 
rats treated with low dose of H. hemerocallidea extract alone. H & E stains. 













Plates 1 (H): Photomicrograph of cross section of liver of Sprague-Dawley 
rats treated with high dose of H. hemerocallidea extract alone. H & E stains. 












Plates 1 (I): Photomicrograph of cross section of liver of Sprague-Dawley rats 
in control. H & E stains. Note: Typical hepatocellular architecture with central 
















Plates 2 (A): Photomicrograph of cross section of liver of Sprague-Dawley 
rats treated with HAART cocktail. PAS stains. Note: Liver architecture 
















Plates 2 (B): Photomicrograph of cross section of liver of Sprague-Dawley rats 
treated with HAART and low dose of H. hemerocallidea. PAS stains. Note: 












Plates 2 (C): Photomicrograph of cross section of liver of Sprague-Dawley rats 
treated with HAART and high dose of H. hemerocallidea. PAS stains. Note: 













Plates 2 (D): Photomicrograph of cross section of liver of Sprague-Dawley 
rats treated with HAART and vitamin C. PAS stains. Note: Liver architecture 















Plates 2 (E): Photomicrograph of cross section of liver of Sprague-Dawley rats 
treated with HAART and vitamin E. PAS stains. Note: Liver architecture with 

















Plates 2 (F): Photomicrograph of cross section of liver of Sprague-Dawley rats 
treated with HAART and vitamin (C and E). PAS stains. Note: Liver 
architecture with glycogen, stellate cells and swollen central vein with 
















Plates 2 (G): Photomicrograph of cross section of liver of Sprague-Dawley 
rats treated with HAART and low dose of H. hemerocallidea extract alone. 














Plates 2 (H): Photomicrograph of cross section of liver of Sprague-Dawley 
rats treated with HAART and high dose of H. hemerocallidea extract alone. 

















Plates 2 (I): Photomicrograph of cross section of liver of Sprague-Dawley rats. 













Plates 3 (A): Photomicrograph of cross section of liver of Sprague-Dawley 
rats treated with HAART cocktail. Massons Trichrome. Note: liver 














Plates 3 (B): Photomicrograph of cross section of liver of Sprague-Dawley rats 
treated with HAART and low dose of H. hemerocalliea. Massons Trichrome 














Plates 3 (C): Photomicrograph of cross section of liver of Sprague-Dawley rats 
treated with HAART and high dose of H. hemerocalliea. Massons Trichrome 
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Plates 3 (D): Photomicrograph of cross section of liver of Sprague-Dawley 
rats treated with HAART and vitamin C. Massons Trichrome stains. Note: 
















Plates 3 (E): Photomicrograph of cross section of liver of Sprague-Dawley rats 
treated with HAART and vitamin E. Massons Trichrome stains. Note: liver 















Plates 3 (F): Photomicrograph of cross section of liver of Sprague-Dawley rats 
treated with HAART and vitamin (C and E). PAS stains. Massons Trichrome 
stains. Note: liver architecture with distorted central vein and congested 














Plates 3 (G): Photomicrograph of cross section of liver of Sprague-Dawley 
rats treated with low dose of H. hemerocallidea extract alone. Massons 














Plates 3 (H): Photomicrograph of cross section of liver of Sprague-Dawley 
rats treated with high dose of H. hemerocallidea. Massons Trichrome stains. 
















Plates 3 (I): Photomicrograph of cross section of liver of Sprague-Dawley rats. 
Control group. Massons Trichrome stains. Note: Normal Liver 

















The liver performs numerous vital metabolic functions, including biochemical, synthetic and 
excretory functions. This central role played by liver in the clearance and transformation of 
chemicals exposes it to toxic injury (Naruse et al, 2007; Saukkonen et al, 2006). Our current study 
revealed that the administration of HAART and H. hemerocallidea concomitantly lead to slight 
changes in the biochemical markers, reduction in qualitative evaluated glycogen and tissue fibrosis 
in this protocol. This in addition to its inability to mitigate hepatocellular morphological changes 
further supports its herbal-drug interaction (HDI) effects. It is possible that unfavorable HDI 
between H. hemerocallidea and HAART could affect efficacy or safety of the later. 
As people living with HIV/AIDs continue to benefit decreased morbidity and mortality due to 
HAART, organ toxicities (especially the liver) are frequently becoming a major concern in view of 
associated consequences that may predispose to metabolic complications. The result of this study 
showed that animals on HAART as well as adjuvant treatment with H. hemerocallidea recorded the 
least body weight gain indicating that H. hemerocallidea exacerbated rather than mitigate the 
probable cause. This is in tandem with the marker of toxicity, the liver-body weight ratio (Table 1) 
which is a sensitive and effective indicator of toxicity and thus important in the identification of 
target organ by toxicants (Asagba et al., 2007). 
The aminotransferases are the most frequently utilized and specific indicators of hepatocellular 
necrosis. These enzymes- aspartate aminotransferase (AST) and alanine amino transferase (ALT) 
catalyze the transfer of the amino acids of aspartate and alanine respectively to the keto group of 
ketoglutaric acid. ALT is primarily localized to the liver but the AST is present in a wide variety of 
tissues like the heart, skeletal muscle, kidney, brain and liver (Friedman et al, 2003; Rosen and 
Keefe, 2000; Thapa and Anuj, 2007).   
Our study revealed an observed increase in the AST levels in the treated groups except in group F 
(HAART with vitamin C and E) animals which was statistically elevated compared with the control, 
this difference may result from herbal-drug interaction (HDI). Whereas the ALT levels of animals 
treated with HAART, HAART with H. hemerocallidea (both doses), HAART with vitamin C and E 
concomitantly statistically decreased as compared with the control. AST is present in both the 
mitochondria and cytosol of hepatocytes, ALT is localized to the cytosol (Rosen and Keefe, 2000; 
Thapa and Anuj, 2007).  
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The activity of AST and ALT in the serum at any moment reflects the relative rate at which they 
enter and leave circulation. Mild elevations are usually seen in drug toxicity, extrahepatic biliary 
atresia (EHBA), fatty liver, cirrhosis, non-alcoholic steato hepatitis (NASH), myositis, duchenne 
muscular dystrophy and even after vigorous exercise (Thapa and Anuj, 2007). Hepatic causes of 
increased serum ALT activity, with or without increased AST activity, include hepatocellular 
necrosis, injury, or regenerative/reparative activity (Boone et al, 2005; Hall, 2001; Meyer and 
Harvey, 2004; Zimmerman, 1999). Decreases in ALT activity have been observed with concurrent 
hepatic microsomal enzyme induction in the rat (Boone et al, 1998) and the decreased ALT levels 
in animals treated with HAART, HAART with H. hemerocallidea (both doses),  
HAART with vitamin C and vitamin E concomitantly were not considered indicative of hepatic 
injury because no substantive concurrent changes in liver histology or liver weight were observed 
except for the animals that were concomitantly administered HAART and high dose H. 
hemerocallidea that shows severe distortions and decreased sinusoidal spaces. The ratio of AST to 
ALT is of use in drug-induced toxicity and alcoholic liver disease. The lack of ALT rise is probably 
due to pyridoxine deficiency. In viral hepatitis the ratio is usually less than one. The ratio invariably 
rises to more than one as cirrhosis develops possibly because of reduced plasma clearance of AST 
secondary to impaired function of sinusoidal cells. 
ALP is an indicator for hepatobiliary injury most found in circulation originates from liver or bone 
(Hagerstrand, 1975; Boone et al, 2005). Current study revealed decreased H. hemerocallidea 
activity in the serum of all animals administered with HAART alone and/or with H. hemerocallidea 
(both doses) and vitamin C and vitamin E. Increased ALP activity from the liver in the absence of 
cholestasis has been reported in dogs with increased endogenous or administered glucocorticoids 
(Meyer and Harvey, 2004; Wiedmeyer et al, 2002) and in rats and dogs with concurrent microsomal 
enzyme induction (Amacher et al, 2001). In rats, intestinal ALP is the major circulating isoenzyme, 
so a transient increase in serum ALP may occur postprandially, whereas fasting and 
hypothyroidism, pernicious anemia, zinc deficiency and congenital hypophosphatasia can result in a 
decrease in serum ALP (Boone et al, 2005).  
Gamma-glutamyl transferease (GGT) is supplemental indicator of hepatobiliary injury, especially 
when evaluated with changes in ALP activity. Its activity in the current study shows no significant 
changes. GGT is a canalicular enzyme whose serum activity is increased in cholestatic liver disease. 
Increases in circulating GGT activity can arise from impaired bile flow and biliary epithelial 
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necrosis (Hall, 2001; Leonard, 1984; Boone et al, 2005). In liver disease GGT activity correlates 
well with alkaline phosphatase levels but rarely the GGT levels may be normal in intra hepatic 
cholestasis like in some familial intrahepatic cholestasis (Jansen and Muller, 2000). Most enzyme 
elevations associated with HAART are moderate, not accompanied by jaundice, and usually 
reversible (Wit et al, 2002). 
As earlier reported by Carr  et al, (1998) that shortly after the introduction of combination 
antiretroviral therapy, a syndrome of subcutaneous lipoatrophy, central adiposity, dyslipidemia, and 
insulin resistance, termed HIV-associated lipodystrophy (HIVLD) was noted. This was initially 
associated with PI exposure, but subsequently exposure to NRTIs (Feeney and Mallon, 2011), 
particularly thymidine analogue NRTIs (tNRTIs) such as Stavudine (Mallal et al., 2000) and 
Zidovudine (Bogner et al., 2001) were also recognized as being central to the development of this 
syndrome.  
In this current study not all lipid parameters were significantly altered as there was no significance 
difference in the total cholesterol levels (p<0.05) while there were significant increase (p<0.05) in 
the serum level of LDL, HDL and except in group G (H. hemerocallidea low dose) as compare with 
the control animals, however the increase was not in folds. More so, the level of triglycerides (TG) 
statistically declined in groups administered with HAART, HAART with H. hemerocallidea and 
HAART with vitamins C and E, whereas its level increases in the group administered with 200 mg 
H. hemerocallidea alone and HAART concomitantly with vitamin C and E as shown in table 1, 
these effect are suspected to be as result of herbal-drug interaction and drug-drug interactions. In 
addition to HIVLD, in the general population there is concern about the increasing prevalence of the 
metabolic syndrome among HIV infected individuals. The pattern of abdominal obesity, low HDL-
C, high triglycerides, and insulin resistance, all seen in HIVLD, are also components of the 
metabolic syndrome (Grundy et al., 2004). An interesting finding which points towards a hepatic 
cause of dyslipidemia is the fact that hepatitis C virus (HCV) co-infection appears to protect against 
the development of HAART-associated dyslipidemia (Di Giambenedetto  et al., 2004; Cooper et al., 
2007; Feeney and Mallon, 2011). This may be due to alterations in hepatocyte lipid secretion – 
mono-infection with HCV genotype is associated with lower serum cholesterol but a marked 
increase in hepatic steatosis. The ultimate result of abnormally functioning subcutaneous adipose 
tissue is reduced storage capacity for circulating lipids resulting in increased circulating free fatty 
acids, reduced adiponectin secretion, and lipid accumulation in non-adipose tissues such as liver 
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(hepatic steatosis) (Feeney and Mallon, 2011) and hepatic triglyceride accumulation which was 
even lower as compared to the control animals in this current study. 
Morphological studies have identified the hepatic tissue as site of attack by HAART, resulting in 
the derangement on the hepatocellular cords and sinusoidal spaces. More so, hepatocellular injury 
has been identified as a potential flaw with most antiretroviral regimen (especially with Nevirapine 
and Stavudine) (Wyatt et al., 2009). Therefore, the deviations in the hepatocellular-architecture in 
HAART-treated group as well as the inability of adjuvant H. hemerocallidea to mitigate the 
derangements rather resulting into hepatocellular distortions suggests that the later having herbal-
drug interaction (HDI). Our result on co-administration of vitamins C and E with HAART does not 
support the concurrent use of these vitamins as supplements by PLWHAs. While there are merits in 
its use as discussed extensively in Azu (2012), accumulating evidence from our laboratory (Azu et 
al., 2014) on the exacerbation of organ injuries has been made previously. It is believed that 
concurrent administration vitamins C and E alter bioavailability, metabolism and pharmacokinetics 
of certain HIV medications raising concerns about the possibility of HAART and vitamin 
supplementation leading to increased toxicity. 
More so, the administration of HAART and H.  hemerocallidea concomitantly leads to reduction in 
qualitative evaluation of glycogen and tissue fibrosis in this protocol. This in addition to its inability 
to mitigate hepatocellular morphological changes further supports its HDI effects. It is possible that 
unfavorable drug-drug interactions between H. hemerocallidea and HAART could affect efficacy or 
safety of the later are possible. Mills et al., 2005 reported that interactions between extracts of H. 
hemerocallidea and antiretroviral drugs inhibit CYP3A4, an isoform of cytochrome P450 and drug 
transporter protein (P-glycoprotein). Many antiretroviral drugs are substrate of CYP3A4 and some 
herbal preparations are known to alter blood levels of these drugs through their effects on CYP3A4 
and p-glycoprotein (Mills et al., 2005). It is therefore reasonable to argue that H. hemerocallidea 
could potentially interact with HIV drug metabolizing enzymes thus patients taking H.  
hemerocallidea extracts concurrently with antiretroviral drugs, may be at risk of developing adverse 
effects which may lead to treatment failure and hepatocellular toxicity. 
Conclusion 
While HAART continues to be fundamental in the management of HIV/AIDS in sub-Saharan 
Africa, the complex issues of toxicities, resistance as well as herbal-drug interactions would 
continue to be hindrance to achieving the desirable goals. It has emerged from this study that 
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hepatotoxicity result based on the histopathological and with little changes in the biochemical 
assessments following HAART with concomitant H. hemerocallidea adjuvants. It is therefore 
advisable to take caution in Hypoxis-HAART combination use as this may impede the ultimate goal 
of HAART. It will be important, therefore, to conduct more in vivo study in healthy volunteers to 
ascertain the true inhibitory effects of these herbal medicines and products in humans. 
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SYNTHESIS, CONCLUSION AND RECOMMENDATION 
3.1      Synthesis 
A number of metabolic consequences have been described in individuals receiving HAART. These 
consequences include derangements in lipodystrophies, insulin resistance, glucose intolerance, 
lactic acidaemia, hepatotoxicity and renal toxicity (Sattler, 2003; Carr, 2003).  
These metabolic complications have been associated with each class of ARV drug (nucleoside 
reverse transcriptase inhibitors [NRTIs], non-nucleoside reverse transcriptase inhibitors [NNRTIs] 
and PIs) (Sattler, 2003; Carr, 2003). Many putative mechanisms have been investigated in these 
classes.  
For instance, hepatotoxicity related to NRTIs has been documented with zidovudine monotherapy 
(Rodriguez et al., 1998). Combination therapy was subsequently found to further increase the risk 
of hepatotoxicity where asymptomatic enzyme elevations greater than five times normal were 
recorded in 30% of patients undergoing antiretroviral treatment (Spengler, 2002). All the nucleoside 
analogues have been implicated but hepatotoxicity were more prevalent with stavudine (d4T), 
didanosine (ddl) and zalcitabine (ddC) (Spengler, 2002). These drugs have a higher affinity for 
mitochondrial polymerase (Moyle, 2000).  
Human mitochondrial DNA polymerase, an enzyme that is required for normal mitochondrial 
replication, is inhibited by nucleoside analogues. Depletion of mitochondrial DNA impairs the 
cellular respiratory chain and inhibits pyruvate and fatty acid oxidation pathways (Lewis et al., 
1995). Mitochondria appear enlarged and swollen with matriceal densities and occasional vacuoles 
on electron microscopy (Lewis et al., 1995). With more severe NRTIs mitochrondrial toxicity, 
microvesicular hepatic steatosis, giant mitochondria and intrahepatic cholestasis are characteristic 
on light microscopy (Burkus, 2002). Clinically, severe NRTI mitochondrial toxicity is manifested 
by the development of hepatomegaly and steatosis and occasionally may be associated with lactic 
acidosis and liver failure (Burkus, 2002). Non-nucleoside analogue reverse transcriptase inhibitors 
(NNRTIs) have also be reported to cause hepatotoxicity with a significant number of patients 
developing abnormal liver function test such as asymptomatic aminotransferase elevations and 
hypersensitivity reaction (Spengler, 2002). The hypersensivity reaction can develop in the first few 
weeks of therapy and may cause symptoms of rash, fever, hypotension along with hepatic 
dysfunction (Wassef and Keizer, 1992). The histological features observed in patients with HAART 
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hepatotoxicity include bile duct injury and proliferation, hepatocellular necrosis and Mallory bodies, 
ballooning of hepatocytes, kupffer cell activation and peri-cellular fibrosis (Kemmer et al., 2000). 
The use of H. hemerocallidea in treatment for PLWHAs is increasing at an apparently much greater 
rate (Nair et al, 2007). However, reports have been documented of the potential drug-drug 
interactions between highly active antiretroviral therapy and H. hemerocallidea (Mills et al., 2005). 
The interactions occur secondary to the effect of HAART on the cytochrome P450- enzyme system 
(Mills et al., 2005). Many antiretroviral drugs are substrates of CYP450 enzymes and some herbal 
extracts are known to be inhibitors of CYP3A4 which is an isoform of CYP450 and drug transporter 
protein (Mills et al., 2005). Inhibition of the CYP3A4 will result in inhibition of antiretroviral drug 
metabolism which potentially lowers the efficacy of the drug resulting in toxicity (Mills et al., 
2005). Thus, knowledge of these drug-drug interactions between H. hemerocallidea and 
antiretroviral regimens are critical in determining whether they can be administered concomitantly 
in PLWHAs and cautionary caveats should be taken in evaluating this in terms of safety and 
efficacy. 
3.2      Conclusion 
While studies to elucidate histomorphological changes in the liver following highly active 
antiretroviral therapy is limited, this research have highlighted that hepatotoxicity is a serious 
complication in patients taking HAART. These perturbations were not attenuated by adjuvant 
treatment with H. hemerocallidea whereupon the histological structures of the liver where disrupt 
leading to a more compromised integrity. 
3.3      Recommendations 
In view of the findings of this research on hepatotoxicity of HAART regimen, we believe that 
although the occurrence of hepatic derangements are prevalent, HIV patients who are clinically and 
virologically stable should continue with HAART unless severe or complex complications emerge. 
If they occur, adequate treatment options for the adverse events are prescribed like regimen change, 
temporarily withdrawal or complete stoppage after a thorough clinical evaluation. Secondly, in view 
of the possible drug-drug interactions likely between H. hemerocallidea and HAART regimen, it is 
recommended that further studies be carried out on the specific active component of H. 
hemerocallidea on this protocol and detailed pharmacokinetic properties thereof. This in addition to 
other investigational parameters would shed light on the possible mechanisms of action of H. 
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